Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study

Relacorilant Demonstrates Sustained Efficacy in Hypertension Control for Patients with Cushing’s Syndrome: Results from the Phase 3 GRACE Study

The Phase 3 GRACE trial demonstrates that relacorilant, a selective glucocorticoid receptor modulator, significantly maintains hypertension control in patients with Cushing’s syndrome without the safety concerns associated with non-selective antagonists, such as adrenal insufficiency or hypokalemia.
TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis

TRIM28: A Novel E3 Ubiquitin Ligase Guarding the Heart Against Ischemia/Reperfusion-Induced Ferroptosis

New research identifies TRIM28 as a critical E3 ubiquitin ligase that degrades IRP2, thereby suppressing iron uptake and preventing myocardial ferroptosis during ischemia/reperfusion injury. This pathway, activated by p55γ and the drug perhexiline, offers a promising therapeutic target for patients with ischemic heart disease.
OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis

OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis

A longitudinal study of 2,260 participants confirms that oral glucose tolerance test (OGTT)-based surrogate indexes, particularly Gutt and Cederholm, are superior to fasting-only measures in predicting type 2 diabetes, providing high clinical utility for metabolic risk stratification.
Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis

Prevalence and Prognostic Significance of Restriction Versus Systolic Dysfunction in Patients With Transthyretin and Light Chain Cardiac Amyloidosis

This large retrospective study of 820 patients reveals that restrictive ventricular physiology is the most common phenotype in cardiac amyloidosis. While preserved LV function offers better initial survival, the rate of progression to restriction is high, emphasizing the need for early clinical detection.
Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

This review synthesizes findings from a 21- **Compiling final edits** Now that I've structured the article, I'm focusing on the final touches, particularly the content for the "Highlights," "Expert Commentary," and the "Conclusion" sections. I'm leveraging the provided literature, including the Dardari et al. study and related papers on GLP-1 agonists and dietary patterns, to build a cohesive narrative. The JSON schema is in its final phase of completion. I have successfully populated the `relative_articles` field. cohort study on 289,875 individuals, demonstrating that severe obesity (BMI ≥35 kg/m²) dramatically elevates risks for heart failure and atrial fibrillation, while revealing significant sex-based differences in stroke and mortality risk.
Angiographic Burden of Coronary Atherosclerosis: The Critical Mediator Between ASCVD Risk Factors and Cardiovascular Outcomes

Angiographic Burden of Coronary Atherosclerosis: The Critical Mediator Between ASCVD Risk Factors and Cardiovascular Outcomes

This Mendelian randomization study reveals that coronary plaque burden significantly mediates the link between traditional risk factors and adverse events like myocardial infarction and heart failure, reinforcing the necessity of early primary prevention to intercept atherosclerosis development.